Valuation: Outlook Therapeutics, Inc.

Market Cap 18Cr 15Cr 14Cr 13Cr 25Cr 1.67TCr 25Cr 170.65Cr 66Cr 826.53Cr 66Cr 65Cr 2.86TCr P/E 2026 *
-2.98x
P/E 2027 * -4.87x
Enterprise Value 18Cr 15Cr 14Cr 13Cr 25Cr 1.67TCr 25Cr 170.65Cr 66Cr 826.53Cr 66Cr 65Cr 2.86TCr EV / Sales 2026 *
147x
EV / Sales 2027 * 3.86x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+2.82%
1 week-8.18%
Current month-8.18%
1 month+87.97%
3 months+585.45%
6 months+147.46%
Current year-7.59%
1 week 1.3
Extreme 1.3
1.63
1 month 0.68
Extreme 0.6752
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
02/06Buy

Director

29,000 0.0181%
28/05
Gms Ventures & Investments
BuyCompany 3,95,16,849 24.6751%
27/05Buy

Chairman

1,22,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+2.82%-8.18%-21.51%-95.52% 17Cr
-1.03%+5.24%+2.94%+9.41% 5.03TCr
+0.25%+1.70%+419.39%+621.71% 4.04TCr
-0.16%+8.42%+28.20%+63.00% 3.44TCr
+1.10%+7.77%+28.18%-3.96% 3.44TCr
+1.31%-0.56%+5.12%+33.90% 2.63TCr
-0.35%+0.09% - - 1.66TCr
-3.33%+3.15%+71.30%+131.94% 1.61TCr
+3.79%+8.88%+106.63%+106.63% 1.37TCr
+0.32%+0.53%+14.33%+21.47% 1.37TCr
Average +0.47%+2.66%+72.73%+98.73% 2.46TCr
Weighted average by Cap. +0.09%+5.07%+95.73%+141.09%

Financials

2026 *2027 *
Net sales 12L 10.5L 10L 9L 17.03L 11Cr 17.3L 1.16Cr 45.13L 5.62Cr 45.05L 44.08L 19Cr 4.57Cr 4Cr 3.69Cr 3.42Cr 6.49Cr 433.99Cr 6.59Cr 44Cr 17Cr 214.19Cr 17Cr 17Cr 740.31Cr
Net income -5.22Cr -4.57Cr -4.21Cr -3.9Cr -7.4Cr -495.23Cr -7.52Cr -50Cr -20Cr -244.41Cr -20Cr -19Cr -844.78Cr -4.23Cr -3.7Cr -3.41Cr -3.16Cr -6.01Cr -401.75Cr -6.1Cr -41Cr -16Cr -198.28Cr -16Cr -16Cr -685.32Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
07/26/07 $1.460 +2.82% 47,31,562
06/26/06 $1.420 -2.07% 73,53,091
02/26/02 $1.450 -1.36% 51,65,541
01/26/01 $1.470 -7.55% 88,11,433
30/26/30 $1.590 -5.92% 58,76,727
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.460USD
Average target price
5.500USD
Spread / Average Target
+276.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock